Gambling disorder is a behavioral addiction that is associated with impairments in value-14 based decision-making such as increased temporal discounting and reduced risk-aversion. 15
repeated-measures counter-balanced placebo-controlled double-blind study. Choice data were 23 fit using hierarchical Bayesian parameter estimation and a modeling scheme that combined a 24 risky choice model with the drift diffusion model to account for both choices and response 25 time distributions. Model comparison revealed that the data were best accounted for by a 26 variant of the drift diffusion model with a non-linear modulation of trial-wise drift rates by 27 value differences, confirming recent findings. Contrary to our hypothesis, risk-taking was 28 slightly increased under tolcapone vs. placebo (Cohen's d = -.281). Examination of drug 29 effects on diffusion model parameters revealed an increase in the value-dependency of the 30 drift rate (Cohen's d = .932) with a simultaneous reduction in the maximum drift rate 31 (Cohen's d = -1.84). These results add to previous work on the potential role of COMT 32 inhibitors in behavioral addictions, and show no consistent beneficial effect of tolcapone on 33 risky choice in gambling disorder. Modeling results add to mounting evidence for the 34 of tolcapone include a reduction of impulsive choice in healthy participants 21 , improved time 69 perception 22 , increased exploration relative to exploitation 23 , and effects on working memory 70 and risk-taking 24 . 71
These behavioral domains generally resonate with domains where gambling disorder 72 is associated with impairments, in particular with respect to decision-making and executive 73 control. A range of studies have shown increased temporal discounting (that is, a greater 74 preference for smaller-sooner over larger-later rewards) in gamblers compared to healthy 75 controls 25 , an effect that is also observed in substance use disorders 26 . Additionally, however, 76 gamblers show reduced risk aversion 25 , such that they over-estimate winning probabilities 77 during risky choice 27, 28 . Risk-taking, in particular for potential gains, is increased following 78 the administration of the dopamine precursor L-DOPA 29, 30 . L-DOPA is converted into 79 dopamine via dopamine decarboxylase, which in the human brain is expressed predominantly 80 in the striatum 31 . L-DOPA might therefore boost dopamine availability more in the striatum 81 than in the cortex. L-DOPA also increases temporal discounting relative to placebo 32 , whereas 82
individual differences in dopamine availability may co-vary with temporal discounting in 83 psychiatric populations but not healthy participants 33 . 84
Taken together, an increase in (presumably predominantly striatal) dopamine might 85 increase impulsivity 32 and risk-taking 29,30 , whereas increasing frontal dopamine levels via 86 COMT inhibition generally tends to improve decision-making and impulse control (with 87 potential effects of COMT genotype status 24 ). Based on these observations, we examined a 88 subset of problem and pathological gamblers from our previous randomized, double-blind, 89 placebo-controlled crossover study 20 to assess whether increasing frontal dopamine levels via 90 the COMT inhibitor tolcapone would reduce risk-taking behavior. Based on recent work in 91 reinforcement learning [34] [35] [36] , temporal discounting, and risky choice 37 we applied a modeling 92 framework based on the drift diffusion model 38 As described in our previous study 20 , subjects were required to be between 18 and 50 years 111 old, in good health, able to read and speak English, and able to provide informed consent. 112
Women of reproductive age were required to be using an effective form of contraception, and 113 to be neither pregnant nor lactating during study participation. A positive urine drug 114 toxicology screen before any visit was grounds for exclusion, as was an alcohol level greater 115 than zero as measured by breathalyzer before any visit. Similarly, subjects were excluded for 116 reported use of psychoactive substances (including both prescription medications and drugs of 117 abuse) within the prior two weeks, use of drugs of abuse more than ten times in the previous 118
year, or current dependence on marijuana. Subjects could otherwise use marijuana no more 119 than three times per week and were required to refrain from marijuana use for at least 48 120 hours prior to testing sessions. These criteria did not apply to nicotine; the two regular 121 smokers (out of four total nicotine-using subjects) were both easily able to refrain for the 122 duration of specific study sessions. Subjects who were taking medications with dopaminergic, 123 serotonergic, or noradrenergic actions (although animal work suggests that tolcapone induces 124 increases in dopaminergic but not noradrenergic concentrations 18 ) or who had a known allergy 125 to either tolcapone or the inert constituents in tolcapone capsules, were also excluded. 126
Likewise, after completion of the Mini International Neuropsychiatric Interview 44 , subjects 127 who met screening criteria for an axis I psychiatric disorder other than gambling disorder, 128 such as major depression, or who had a significant medical or psychiatric illness requiring 129 treatment, were excluded from participating. Because tolcapone carries the potential for 130 hepatotoxicity, liver function tests as assessed by phlebotomy were required to be no more 131 than three times the upper limit of normal. 
Risk-taking task 145
On each testing day, participants completed 96 trials of a risky-choice task involving a series 146 of choices between a smaller, certain reward ($10 with 100%) and larger, but riskier, options. 147
A first set of risky options consisted of all combinations of sixteen reward amounts (10.1, 148 10.2, 10.5, 11, 12, 15, 18, 20, 25, 30, 40, 50, 70, 100, 130, 150 dollars) and seven 149 probabilities (10%, 17%, 28%, 54%, 84%, 96%, 99%). We used a second set of probabilities 150 (11%, 18%, 27%, 55%, 83%, 97%, 98%) in combination with the same series of reward 151 amounts to create a second set of 96 trials. The assignment of the two sets of trials to the two 152 drug conditions was randomized across participants. The experiment was implemented in 153 Presentation © (Neurobehavioral Systems). Trials were presented in randomized order and 154 with a randomized assignment of safe/risky options to the left/right side of the screen. Both 155 options remained on the screen until a response was made. 156 157
Computational modeling 158

Risky choice model 159
We applied a simple single-parameter discounting model to describe how value changes as a 160 function of probability, such that discounting is hyperbolic over the odds against winning the 161 gamble 48 : 162
Here, A is the numerical reward amount of the risky option, is the odds against winning and 163 I is an indicator variable that takes on a value of 1 for tolcapone data and 0 for placebo data. 164
The model has two free parameters: h is the hyperbolic discounting rate from the placebo 165 condition (modeled in log-space) and s is a weighting parameter that models the degree of 166 reduction in discounting under tolcapone vs. placebo. 167
168
Softmax action selection 169
Softmax action selection models the choice probabilities as a sigmoid function of value 170 differences 49 : 171
Here, SV is the subjective value of the risky reward according to Eq. 1 and is an inverse 172 temperature parameter, modeling choice stochasticity (for = 0, choices are random and as 173 increases, choices become more dependent on the option values). 174 175
Drift diffusion choice rule 176
To better characterize the dynamics of the decision process, we replaced the softmax choice 177 rule (Eq. 2) with the drift diffusion model (DDM), based on recent work in reinforcement 178 learning 34-36 . The DDM accounts not only for binary choices but for the full reaction time 179 distributions associated with those decisions. We used the Wiener Module 50 for the JAGS 180 statistical modeling package 51 that implements the likelihood function of a Wiener diffusion 181 process. The DDM assumes that decisions arise from a noisy evidence accumulation process 182 that terminates as the accumulated evidence exceeds one of (usually) two decision bounds. 183
Reinforcement learning applications of the DDM have used accuracy coding to define the 184 response boundaries of the DDM 34-36 , such that the upper boundary corresponds to selections 185 of the objectively superior stimulus, and the lower boundary to choices of the inferior option. 186
This structure is in line with the traditional application of the DDM in the context of 187 perceptual decision-making tasks 52 . However, in value-based decision-making, there is 188 typically no objectively correct response. Therefore, previous applications of the DDM in this 189 domain have instead re-coded accuracy to correspond to the degree to which decisions are 190 consistent with previously obtained preference judgements 53 . This approach is not possible, 191 however, when the goal is to use the DDM to model the preferences that in such a coding 192 scheme would determine the boundary definitions. Therefore, here we applied stimulus 193 coding, such that the upper boundary (1) corresponded to the selection of the risky option and 194 the lower boundary (0) to the selection of the certain option. 195
We used percentile-based cut-offs for RTs, such that for each participant, the fastest 196 and slowest 2.5% of trials were excluded. RTs for choices of the certain 100% option were 197 then multiplied by -1 prior to model estimation. The RT on a given trial is then distributed 198
Here, is the boundary separation (modeling response caution / the speed-accuracy trade-200 off), z is the starting point of the diffusion process (modeling a bias towards one of the 201 decision boundaries), is the non-decision time (reflecting perceptual and/or response 202 preparation processes unrelated to the evidence accumulation process) and v is the drift rate 203 (reflecting the rate of evidence accumulation). In the JAGS implementation of the Wiener 204 model 50 , the starting point z is coded in relative terms and takes on values between 0 and 1. 205
That is, z = .5 reflects no bias, z >.5 reflects a bias towards the upper (risky option) boundary, 206 and z <.5 reflects a bias towards the lower (certain option) boundary. 207
We then compared three variants of the DDM: First, we examined a null model 208 (DDM 0 ) without any value modulation. In this model, the four DDM parameters ( , , z, and 209 v) were held constant across trials. Drug effects were modeled by including a term modeling a 210 tolcapone-induced change relative to the placebo condition for each parameter. Second, we 211 examined two previously proposed functions linking trial-by-trial changes in the drift rate v to 212 value-differences. We examined a linear mapping (DDM lin ) as proposed by Pedersen et al. 213 (2017) 34 : 214
Here, v coeff maps trial-wise value differences onto the drift rate v. SV is the subjective value of 215 the rewards according to Eq. 1. 216
217
We also examined a recently proposed non-linear (DDM S ) scheme 35 : 218
Here, S is a sigmoid function centered at 0 with m being the scaled value difference from Eq. 219 5, and asymptote ± v max . For DDM lin and DDM S , effects of choice difficulty on response times 220 naturally arise. For more similar values, the trial-wise drift rate approaches 0. 221 222
Hierarchical Bayesian models 223
Model building proceeded as follows. As a first step, all models were fit at the level of 224 individual participants. We validated that good fits could be obtained, such that posterior 225 distributions were centered at sensible parameter values and the Gelman-Rubin statistic, an 226 estimate of the degree of Markov chain convergence (see below), was in an acceptable range 227 of 1 ≤ ≤ 1.01. In a second step, models were fit in a hierarchical manner with group-level 228 distributions for all parameters. We used the same convergence criteria as for the single-229 subject models (1 ≤ ≤ 1.01). For group level hyper-parameters, we used uninformative 230 priors (i.e. uniform distributions for means defined over sensible ranges, gamma distributions 231 for precision). Here, models were fit separately to the data from the placebo and tolcapone 232 conditions, to examine whether drug administration altered the relative model ranking. 233
Finally, after identifying the variant of the drift diffusion model that accounted for both the 234 placebo and tolcapone data best, we fit this model across drug conditions. In this final 235 combined model, parameters from the placebo condition were modeled as the "baseline", and 236 all drug effects were modeled as Gaussians with group level priors with = 0, = 2. All 237 JAGS model code is available on the Open Science Framework (https://osf.io/wtg89/). 
Posterior predictive checks 251
We additionally performed posterior predictive checks to ensure that the best-fitting model 252
captured key aspects of the data. Therefore, during model estimation, we simulated 10k full 253 datasets from the hierarchical models based on the posterior distribution of parameters. For 254 each participant and drug condition, model-predicted RT distributions for a random sample of 255 1k of these simulated data sets were then smoothed with non-parametric density estimation 256 (ksdensity.m in Matlab) and overlaid on the observed RT distributions for each subject and 257 drug condition. 258 259
Analysis of drug effects 260
We characterize drug effects in the following ways. First, we show group posterior 261 distributions for all parameters, and 85% and 95% highest density intervals for the posterior 262 
285
Results 286
Model-free analyses 287
Response time (RT) distributions across participants per drug condition are shown in Figure  288 1a. Arcsine-square-root transformed risky choice ratios (Figure 1b 
Model comparison 293
We then compared three variants of the DDM: a null model without any value modulation 294 (DDM 0 ), a model with a linear scaling of trial-wise drift rates (DDM lin ) and a model with non-295 linear (sigmoid) drift rate scaling (DDM S ). To ensure that drug condition did not impact 296 model ranking, we first fit the three models separately to the data from the placebo and 297 tolcapone conditions. As can be seen from Table 2, model ranking was the same in the two 298 drug conditions, such that models including value modulation of the drift rate outperformed 299 the DDM 0 , and the non-linear DDM S fit the data better than the DDM lin . 300 301 
Effects of tolcapone on risk-taking and diffusion model parameters 352
We next examined the posterior distributions of parameters of the final DDM S model in more 353 detail. Figure 3 corresponding values in these two groups. Gamblers also exhibited a bias towards the safe 360 option, reflected in a posterior distribution of the starting point that was shifted slightly 361 towards zero (Fig. 3c ), but was numerically more similar to the mOFC patient group than to 362 the control group. The maximum drift rate v max at placebo was numerically higher in the 363 (Fig. 3d ) and there was a robust positive effect of value-differences on the trial-wise 364 drift rates, as reflected in a positive drift rate coefficient parameter under placebo (v coeff , Fig.  365 3e). Interestingly, log(h) (i.e. risk-taking) in the gamblers under placebo (Fig. 3f) was 366 qualitatively more similar to risk-taking behavior of the mOFC patients than that of the 367 controls from our previous study. 368
All drug effects are summarized in Table 2 (mean parameter changes between  369 tolcapone and placebo, standardized effect sizes (Cohen's d) , Bayes Factors for directional 370 effects; see methods section). The posterior distributions for the tolcapone-induced change for 371 boundary separation (Fig. 3a) , non-decision time (Fig. 3b ) and starting point (Fig. 3c) 
391
Consistency of tolcapone effects across participants 392
We next examined the consistency of the latter three group effects across participants by 393 overlaying individual posterior distributions for the tolcapone-effects over the average group 394 effects for parameters showing drug-effects at the group level ( Figure 4 : v max , Figure 5 : v coeff , 395 Figure 6: log(h) ). Under tolcapone, 13/14 participants showed and a mean reduction in the 396 maximum drift rate v max , 12/14 showed an increase in the drift rate scaling v coeff , and 9/14 397 showed an decrease in log(h) (increase in risk-taking). For transparency, we have highlighted 398 the three Met/Met genotype participants in these plots (red lines), being fully aware that 399 interpretation of genotype effects in such a small sample is unwarranted Gambling disorder is associated with impairments in value-based decision-making, including 403 increased temporal discounting and reduced risk aversion 25 . Here we tested whether risk-404 taking in problem and pathological gamblers could be attenuated by the COMT inhibitor 405 tolcapone, which predominantly increases dopamine levels in the frontal cortex. Choice data 406 were modeled in a hierarchical Bayesian scheme with the drift diffusion model as the choice 407 rule to account for both choices and reaction time distributions. In contrast to our initial 408 hypothesis, if anything tolcapone increased risk-taking (small effect size). Examination of the 409 drift diffusion model parameters showed a reduction in the maximum drift rate under 410 tolcapone (large effect size) and an increase in the value-dependency of the drift rate (large 411 effect size). 412
We used a modeling scheme based on the drift diffusion model, which has recently 413 gained some popularity in reinforcement learning and value-based decision-making [34] [35] [36] [37] . As in 414 our previous work 37 , choice model parameters estimated via a standard softmax function 415 could be reliably reproduced using the diffusion model as the choice rule. Posterior predictive 416 checks revealed that the best fitting drift diffusion model reproduced individual subject 417 reaction time distributions reasonably well in both drug conditions. In keeping with previous 418 work 35,37 , we again carried out a model comparison and evaluated both a linear and non-linear 419 mapping from value-differences to trial-wise drift rates. The DDM S fit the data better in both 420 drug conditions, confirming previous results in non-linear drift rate scaling. 421
Our results suggest small effects (|d|<.1) of tolcapone on three parameters of the drift 422 diffusion model: boundary separation, non-decision time and starting point (bias). This 423 finding suggests that overall response caution (as reflected in the boundary separation 424 parameter) and processes related to motor preparation and/or stimulus processing (as reflected 425 in the non-decision time) were largely unaffected by tolcapone. Since group differences for 426 these parameters are potentially confounded by age, we do not discuss them further. Likewise, 427 gamblers under placebo showed a bias towards the safe option (z placebo = .473, see Figure 3c ) 428 that was similar to the bias exhibited by both medial orbitofrontal cortex lesion patients and 429 controls in our previous study using the same risk-taking task 37 (z mOFC = .478, z controls = .461), 430 but numerically closer to the patient's bias. Note that gamblers under placebo also exhibited a 431 level of risk-taking that was numerically even more pronounced than that of the medial 432 orbitofrontal cortex lesion patients from our previous study 37 (log(h) placebo = 1.68, log(h) mOFC = 433 1.81, log(h) controls = 2.26). Under tolcapone, this risk-taking increased even further 434 (log(h) tolcapone = 1.39). Despite the absence of a specific control group for the present sample of 435 pathological and problem gamblers, this finding nonetheless suggests that risk-taking 436 behavior was quite pronounced in the gamblers, and puts the drug-effect in perspective. 437
Taken together with the observation regarding the bias, this further indicates that risk-taking 438 might be generally associated with reduced bias for the safe option. 439
What mechanism might drive the observed effects of tolcapone on risk-taking and 440 value evidence accumulation? Our approach was motivated by the idea that tolcapone might 441 attenuate risk-taking via an augmentation of prefrontal cortex (top-down control) functions. 442
The lateral prefrontal cortex is implicated in cognitive control 56,57 , and disruption of prefrontal 443 cortex function can increase risk-taking and impulsivity 37,58-61 . Likewise, tolcapone has been 444 shown to act through an enhancement of prefrontal cortex activation and /or fronto-striatal 445 interactions 16, 20, 21 . However, although the drug-effect on risk-taking was small, it was in the 446 opposite direction, increasing risk-taking rather than attenuating it. Furthermore, the 447 directionality and effect size of the drug-effect on risk-taking showed some heterogeneity 448 across participants ( Figure 6 ). In the absence of task-related imaging data, drawing definite 449 conclusions regarding the mechanism underlying these differential effects of tolcapone on 450 risk-taking remains speculative, and individual genetic differences likely contribute to these 451 variable results. 452
Similarly, it remains unclear through what exact mechanism an increase of frontal 453 dopamine levels might affect the changes in value-dependency of the drift-rate observed in 454 the present study. Ventromedial prefrontal cortex is involved in coding for reward valuation 455 during learning and decision-making 62,63 . It could thus be speculated that tolcapone might 456 enhance such value representations, thereby increasing the value-dependency of trial-wise 457 drift rates. However, at the same time maximum drift rates were reduced under tolcapone, an 458 effect that was consistent across participants (see Figure 4 ). This might reflect at a trade-off 459 between vmax and vcoeff parameters in the model, such that reduced vmax can be 460 compensated for by increases in vcoeff in some conditions. Such interactions require further 461 study in the use of diffusion model based choice rules. 462
Finally, dopamine has different functions in different prefrontal cortex subregions 64 , 463 such that different dopamine-dependent cognitive functions might exhibit different dose-464 response functions 65 and thus be differentially modulated by tolcapone. A thorough 465 assessment of these complexities, including process-dependent baseline effects and potential 466 subregion-specific effects of tolcapone will need to be more fully addressed in future studies. 467
While we genotyped participants for the COMT Val158Met polymorphism, drawing 468 any conclusions regarding genotype effects in a small sample study such as the present one is 469 obviously highly problematic. On the other hand, not reporting genotype data that is available 470 would also seem inappropriate given the previously suggested COMT genotype-dependency 471 of tolcapone effects on risk-taking 24 . In their between-subjects study, Farrell and colleagues 24 472 reported increased risk-aversion in Val/Val participants under tolcapone, compared to a group 473 of Met/Met carriers. In contrast to that study, in our data set the two participants showing the 474 largerst reduction in risk-taking under tolcapone were Met/Met carriers. This result is in line 475 with the frequent observation that dopamine effects on cognitive functions mediated by the 476 prefrontal cortex depend on baseline dopamine availability in an inverted-U-shaped fashion 66 . 477
Yet, in this model, Met/Met carriers exhibit a higher frontal dopamine level at baseline due to 478 the COMT enzyme being less active. Further COMT suppression (e.g. via tolcapone) is then 479 thought to move Met/Met subjects into an "overdosed" state, impairing performance relative 480 to placebo 24,66,67 . This is not compatible with the substantial reduction in risk-taking observed 481 for 2/3 Met/Met carriers. However, as mentioned above, different functions might show 482 different functional forms of dopamine baseline-dependency 62 , which would require much 483 larger subject numbers to fully evaluate. 484
There are several additional limitations of the present study that need to be 485 acknowledged. First, given the small sample size, our findings require replication in larger 486 samples and groups other than pathological and problem gamblers. Second, although gender 487 was relatively balanced in the present study, which is often not the case in studies involving 488 pathological and problem gamblers, we were obviously underpowered to examine sex 489 differences. Third, we did not test a control group specifically matched to the gamblers. 490
Rather, we focused exclusively on potential drug-effects in a group of pathological and 491 problem gamblers. The aim of the project was to examine the degree to which behavioral 492 markers of gambling disorder such as risk-taking and temporal discounting 20 could be 493 improved by COMT inhibition, but future studies could benefit from a more detailed 494 exploration of the effects of COMT inhibition on risk-taking in healthy controls, as previously 495 done for inter-temporal choice 21 . However, to provide some reference for the level of risk-496 taking behavior in our particular sample of pathological and problem gamblers, we have 497 plotted parameters for a group of medial orbitofrontal cortex lesion patients and controls from 498 a previous study 37 . 499
Taken together, our data extend previous investigations of modeling schemes that 500 build on the drift diffusion model 34-37 , by successfully applying this approach for the first time 501 in a group of problem and pathological gamblers. While the data are preliminary given the 502 small sample size, they suggest that tolcapone might impact aspects of value evidence 503 accumulation during risky choice. However, our data do not support the idea that tolcapone 504 consistently attenuates risk-taking in pathological and problem gamblers. These results extend 505 and complement previous examinations of the potential of COMT inhibition in gambling 506 disorder 16, 20 by providing a comprehensive model-based analysis of risky decision-making. 
